Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China.
Liu, B., Song, Y., & Liu, D. (2017). Clinical Trials of CAR-T Cells in China. Journal of Hematology & Oncology, 10 (1), 166. https://doi.org/10.1186/s13045-017-0535-7
Originally published in Journal of Hematology & Oncology 2017 10:166. The original material can be found here.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.